NNBP Nanobac Pharmaceuticals Inc (CE)

TAMPA, FL ("Nanobac" or "the Company") is pleased to announce the signing of a research collaboration agreement with BioChemics Inc. (BCI) to utilize BCI's leading patented drug delivery technology (VALE�) for the transdermal (topical) delivery of Nanobac compounds for the treatment of prostatitis. Terms of the deal include upfront payments already made, future payments, R&D support as well as milestones for success for BCI.

"The Company believes that utilizing BCI's proprietary transdermal therapeutic delivery system will be beneficial to prostatitis patients due to a more targeted approach of the active ingredient/molecule," said Dr. Benedict Maniscalco, Co-Chairman and Chief Medical Officer of Nanobac Pharmaceuticals. "Through this collaboration with BCI we have now gained access to a promising targeted drug therapy that potentially allows us to address an area of high medical importance where current therapies are clearly inadequate," Dr. Maniscalco concluded.

"Based on the nature of this disease, we believe that the combination of Nanobac's active pharmaceutical agent combined with BCI's drug delivery technology may provide a more efficacious treatment therapy for patients suffering from prostatitis," said John J. Masiz, Esq., President & CEO of BioChemics. "BCI is extremely excited about this collaboration because we see the broader applications in this and other diseases where a targeted transdermal approach may be a better option than oral or i.v. routes of administration," concluded Masiz.

About Prostatitis/CPPS

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) suggest that Prostatitis might account for up to 25 percent of all office visits by young and middle-aged men for complaints involving the genital and urinary systems. The term prostatitis actually encompasses four disorders: Acute bacterial prostatitis, chronic bacterial prostatitis, chronic prostatitis/chronic pelvic pain syndrome (CPPS) and Asymptomatic inflammatory prostatitis. CPPS is the most common but least understood form of prostatitis. It is found in men of any age and its symptoms have a profound effect on quality of life. Symptoms include pain (pelvic and genitals), urinary frequency and erectile dysfunction.

About Nanobac Pharmaceuticals

Nanobac Pharmaceuticals is the leader in research and treatment of degenerative diseases stemming from nanobacterial infections. This infection is implicated in the formation of disease-causing calcification and plaque in the circulatory system and vital organs. Nanobac Pharmaceuticals markets diagnostics and prescription nanobiotic medications demonstrated to safely and effectively treat an underlying cause of atherosclerosis, coronary heart disease and other degenerative diseases. Nanobac Pharmaceuticals Inc. is headquartered in Tampa, Florida. For more information, visit our website at: http://www.nanobac.com.

About BioChemics, Inc.

BioChemics is a pharmaceutical company that has developed a novel, transdermal drug delivery system for the first time that may allow almost any drug to be efficiently delivered through the skin. The transdermal technology, called VALE� (Vaso-active Lipid Encapsulated), may allow a substantial portion of the pharmacopeia to be re-engineered, turning oral drugs into transdermals that are safer (no gastro-intestinal problems), cheaper and potentially faster acting (applied directly to the treated area) than oral equivalents. The company's focus is on multi-billion dollar market opportunities currently underserved by existing therapies. The company's two lead clinical products focus on treating diabetic neuropathy and osteoarthritis. Founded in 1989, the Company is headquartered in Danvers, Mass. Additional information is available at www.biochemics.com.

Investors are cautioned that certain statements in this document, some statements in periodic press releases and some oral statements of Nanobac Pharmaceuticals, Inc. officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future Nanobac Pharmaceuticals, Inc. actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and Nanobac Pharmaceuticals, Inc. has no specific intention to update these statements.

VALE� is a registered trademark of BioChemics, Inc.

Contact: Nanobac Pharmaceuticals, Tampa Brady Millican 813-264-2241 Email Contact BioChemics, Inc. David H. Donabedian, Ph.D. COO & SVP, Business Development (978) 750-0090

Nanobac Pharmaceuticals (CE) (USOTC:NNBP)
Gráfica de Acción Histórica
De Abr 2024 a May 2024

Nanobac Pharmaceuticals (CE) (USOTC:NNBP)
Gráfica de Acción Histórica
De May 2023 a May 2024